Pharmaceutical Compositions with NSAID and Fatty Acid Oxidase Inhibitor for Treating Infections, Inflammation, Aging
Summary
The USPTO granted patent US12599614B2 to MD VAULT LLC for pharmaceutical compositions combining non-steroidal anti-inflammatory drugs (NSAIDs) with fatty acid oxidation inhibitors for treating microbial infectious diseases, associated inflammatory disorders, and aging-related conditions. The patent, filed December 13, 2021, contains 9 claims and covers compositions including agents such as diclofenac (A61K 31/616), mefenamic acid (A61K 31/495), and phenylbutazone (A61K 31/192).
What changed
The USPTO granted patent US12599614B2 to MD VAULT LLC, establishing intellectual property rights for pharmaceutical compositions containing NSAID therapeutic agents combined with fatty acid oxidation inhibitors. The patented compositions are directed to treatment and prophylaxis of microbial infectious diseases, associated inflammatory disorders, and aging-related diseases.
This patent grant does not create compliance obligations for the public. Competitors developing anti-inflammatory, anti-aging, or anti-infective formulations should monitor this grant for potential infringement implications on freedom-to-operate assessments.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and pharmaceutical compositions for the treatment and prophylaxis of microbial infectious diseases and associated inflammatory disorders and for the treatment and prophylaxis of aging and associated diseases
Grant US12599614B2 Kind: B2 Apr 14, 2026
Assignee
MD VAULT LLC
Inventors
Meng Hua Ng
Abstract
A pharmaceutical composition and method are provided which may be used for the treatment and prevention of various infections, diseases, and conditions. Preferably, the composition and method may be used for preventing and treating of aging and aging associated disease and its use (or method). Preferably, the composition and method may be used for treating and prophylaxis of microbial infectious diseases and associated inflammatory disorders and its use (or method). The pharmaceutical composition according to the invention includes a therapeutic agent X or a pharmaceutically acceptable salt thereof; a therapeutic agent Y or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient, in which the therapeutic agent X is a non-steroidal anti-inflammatory drug and the therapeutic agent Y is a fatty acid oxidation inhibitor.
CPC Classifications
A61K 31/616 A61K 31/495 A61K 31/192 A61K 31/196 A61K 31/205 A61K 31/336 A61K 31/415 A61K 31/444 A61K 45/06 A61P 29/00 A61P 31/10 A61P 39/06 Y02A 50/30
Filing Date
2021-12-13
Application No.
18039236
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.